New hope for Hard-to-Treat cancers: first human trial of ISM3412 begins
NCT ID NCT06414460
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called ISM3412 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check the drug's safety and find the best dose. About 80 participants will take part in two stages: first to find a safe dose, then to confirm it works well enough for further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED / METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
-
Community Cancer Center North
RECRUITINGIndianapolis, Indiana, 46250-2042, United States
-
Jiangsu Provincial People's Hospital
RECRUITINGNanjing, Jiangsu, China
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
-
Shanghai Gobroad Cancer Hospital
RECRUITINGShanghai, Shanghai Municipality, China
-
Smilow Cancer Hospital at Yale New Haven Breast Center
RECRUITINGNew Haven, Connecticut, 06520-8028, United States
Contact
-
Sun Yat-sen university cancer center
RECRUITINGGuangzhou, Guangdong, 510030, China
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-4095, United States